This is a working overview of lipogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-16. Anything still debated is marked as such rather than presented as settled.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
== History == Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell. In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016. In June 2017, Sarepta Therapeutics appointed former Allergan executive Doug Ingram as its new CEO to replace Edward Kaye who had announced plans to step down earlier that year.
Human Genome Project (HGP) A collaborative international scientific research project with the goal of sequencing all of the chromosomal DNA and identifying and mapping all of the genes within human cells, and ultimately of assembling a complete reference genome for the human species. The project was launched in 1990 by a consortium of federal agencies, universities, and research institutions and was declared complete in 2003. Because each individual human being has a unique genome, the finished reference genome is a mosaic of sequences obtained by sampling DNA from thousands of individuals across the world and does not represent any one individual.
Cl2 + H2O ⇌ HClO + HCl Cl2 + 4 OH− ⇌ 2 ClO− + 2 H2O + 2 e− Cl2 + 2 e− ⇌ 2 Cl− When acids are added to aqueous salts of hypochlorous acid (such as sodium hypochlorite in commercial bleach solution), the resultant reaction is driven to the left, and chlorine gas is formed. Thus, the formation of stable hypochlorite bleaches is facilitated by dissolving chlorine gas into basic water solutions, such as sodium hydroxide. The acid can also be prepared by dissolving dichlorine monoxide in water; under standard aqueous conditions, anhydrous hypochlorous acid is currently impossible to prepare due to the readily reversible equilibrium between it and its anhydride:
lack of resistance to permanent deformation, resisting only relative rates of deformation in a dissipative, frictional manner, and the ability to flow (also described as the ability to take on the shape of the container). These properties are typically a function of their inability to support a shear stress in static equilibrium. By contrast, solids respond to shear either with a spring-like restoring force—meaning that deformations are reversible—or they require a certain initial stress before they deform (see plasticity). Solids respond with restoring forces to both shear stresses and to normal stresses, both compressive and tensile. By contrast, ideal fluids only respond with restoring forces to normal stresses, called pressure: fluids can be subjected both to compressive stress—corresponding to positive pressure—and to tensile stress, corresponding to negative pressure. Solids and liquids both have tensile strengths, which when exceeded in solids creates irreversible deformation and fracture, and in liquids cause the onset of cavitation. Both solids and liquids have free surfaces, which cost some amount of free energy to form. In the case of solids, the amount of free energy to form a given unit of surface area is called surface energy, whereas for liquids the same quantity is called surface tension. In response to surface tension, the ability of liquids to flow results in behaviour differing from that of solids, though at equilibrium both tend to minimise their surface energy: liquids tend to form rounded droplets, whereas pure solids tend to form crystals.
Sources: en.wikipedia.org
== Remission == Remission occurs when a cat no longer requires treatment for diabetes and has normal blood glucose concentrations for at least a month. Approximately one in four cats with type 2-like diabetes achieves remission. Some studies have reported a higher remission rate than this, which may in part be due to intensive monitoring that is impractical outside of a research environment. Research studies have implicated a variety of factors in successful remission; in general, the following factors increase the likelihood of remission:
==== The role of baroreceptors ==== Pressure-sensitive baroreceptors are found in the vessel walls of nearly all large arteries in the thorax and neck, but are particularly plentiful in the sinuses of the carotid arteries and in the arch of the aorta. These specialized receptors are sensitive to changes in mean arterial pressure. An increase in sensed pressure results in an increased rate of firing by the baroreceptors and a negative feedback response, lowering systemic arterial pressure. Aldosterone release causes sodium and water retention, which causes increased blood volume, and a subsequent increase in blood pressure, which is sensed by the baroreceptors. To maintain normal homeostasis these receptors also detect low blood pressure or low blood volume, causing aldosterone to be released. This results in sodium retention in the kidney, leading to water retention and increased blood volume.
=== Characterization of engineered proteins === Many applications of protein engineering for drug discovery or biophysics applications involve modification of the protein amino acid sequence through truncation, domain fusions, site-specific modifications or random mutagenesis. Thermofluor provides a high throughput method for the evaluation of the effects of such sequence variations on protein stability as well as means for developing stabilizing conditions if required.
Sources: en.wikipedia.org
=== Collagen fibers === Type I collagen comprises approximately 85-95% of the organic matrix, providing the structural scaffold and tensile strength necessary for bone formation. These collagen fibers form a dense, highly cross-linked network that serves as the foundation for subsequent mineralization. The collagen molecules are arranged in layers that alternate parallel and orthogonal to the axis of stress loading, creating a sophisticated composite structure.
== History == Was first partially isolated and purified from a serum that contained chondrocytes from chick embryos in 1981 by scientists/researchers A. Tyl Hewitt, Hugh H. Varner, Michael H. Silver, Waltraud Dessau, Charlotte M. Wilkes, and George R. Martin. This group would later go on in the study and deem this attachment factor that they found to be chondronectin.[7] It was then found in human fetal cartilage and human serum. Early scientists focused on proving that chondronectin was its own separate protein. They needed to show that it was not just another molecule that had already been identified. By the 1980s, newer studies gave researchers more evidence about its role in supporting cartilage and surrounding cells. Finding it in many biological samples also showed that it exists in different species. It is not limited to only one type of tissue. In 1987, chondronectin was isolated from articular cartilage from a canine by researchers Nancy Burton-Wurster, Valerie J. Horn, and George Lust. It was then reported to be in human synovial fluid in a 1988 study done by Steven Carsons and Valerie J. Horn. How they did this was by using a monoclonal antibody that was used in a linked immunosorbent assay (ELISA), along with a Western blot assay to observe the protein in synovial fluid. Scientist found chondronectin in both joint fluid and cartilage. This find made researchers wonder if it helps keep joints healthy. In the past, experts used it as a simple tool to help cells stick to a surface. Now they see it as a vital part of connective tissue research.
== Causes == The exact causes of autoimmune diseases remain largely unknown; however, research has suggested that a combination of genetic, environmental, and hormonal factors, as well as certain infections, may contribute to the development of these disorders. The human immune system is equipped with several mechanisms to maintain a delicate balance between defending against foreign invaders and protecting its own cells. To achieve this, it generates both T cells and B cells, which are capable of reacting with self-proteins. However, in a healthy immune response, self-reactive cells are generally either eliminated before they become active, rendered inert via a process called anergy, or their activities are suppressed by regulatory cells.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.